Pifeltro

Chemical Namedoravirine
Dosage FormTablet (oral; 100 mg)
Drug ClassAntivirals
SystemBlood
CompanyMerck & Co.
Approval Year2018

Indication

  • Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg with no prior antiretroviral treatment history, or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine.
Last updated on 7/25/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Pifeltro (Doravirine) Prescribing Information.2018Merck & Co., Inc., Rahway, NJ